For years, the tobacco behemoth Altria has attracted income-focused investors with its substantial dividend payouts. However, a closer examination reveals significant cracks in the foundation beneath this attractive yield. Recent data points to an alarming collapse in the company’s core profit engine, casting a long shadow over its long-term earnings potential. What many perceive as a stable “value” investment may, in fact, pose a substantial risk to investment portfolios.
A Bleak Earnings Forecast Extends Beyond the Present
Concerns are not limited to recent quarterly performance. Fresh analysis paints a pessimistic outlook for the coming years. Projections suggest profits could shrink to approximately $9.1 billion by 2028, marking a notable decline from current levels. Revenue, too, is at risk of stagnation. Compounding these issues is the struggle of NJOY, Altria’s designated hope in the e-cigarette segment, which is entangled in patent disputes and failing to deliver meaningful growth momentum. For investors banking on a stable future, these projections serve as clear warning signals.
The Marlboro Cash Cow Faces Accelerated Decline
The latest figures deliver a sharp blow: Marlboro cigarette sales volume plummeted by a worrying 11.7% in the most recent quarter. This decline is significantly steeper than the already contracting total market, which shrank by 8.2%. Historically, Altria has offset falling shipment volumes with aggressive price increases. Yet, the current drop is so severe that this strategy is reaching its limits. The company’s pricing power is eroding, and its transition to smoke-free products continues to lag behind competitors.
Should investors sell immediately? Or is it worth buying Altria?
Wall Street’s Divided Verdict Reflects Underlying Uncertainty
Despite these fundamental challenges, consensus on Wall Street remains elusive. While some analysts, including those at Goldman Sachs, continue to see potential due to the company’s massive cash flow, broader market skepticism is growing. Currently trading at €50.13, the stock has shed roughly 2% of its value since the start of the year—a direct reflection of this prevailing uncertainty.
The central question for shareholders is this: can the current dividend yield of approximately 7.5% be sustained indefinitely if earnings contract as forecast? Investors would be wise to monitor closely whether Altria meets its 2025 profit targets. Any downward deviation will likely severely undermine confidence in the stability of its famed payouts.
Ad
Altria Stock: Buy or Sell?! New Altria Analysis from December 4 delivers the answer:
The latest Altria figures speak for themselves: Urgent action needed for Altria investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 4.
Altria: Buy or sell? Read more here...
